Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886596 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 26,675
- Enrollment target
NCT04886596 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 26,675 participants.
The verdict
NCT04886596, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26,675 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSVPreF3 OA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26,675 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04886596
The ClinicalTrials.gov registry entry for NCT04886596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26,675 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04886596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04886596 about?
NCT04886596 is a clinical study titled "Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above". This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and i...
What is the current status of trial NCT04886596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26,675 participants. The study started on 2021-05-25. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT04886596?
The interventions under investigation include: Placebo (BIOLOGICAL), RSVPreF3 OA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04886596?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.